Charlottesville, VA – According to filings with the U.S. Securities and Exchange Commission, Ampel is raising $4,000,000.00 in new funding. Sources indicate as part of senior management Chief Operating Officer, Amrie Grammer played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ampel

AMPEL is a precision medicine company raising funds for 2022 commercialization of a first-in-class CLIA-certified gene-based LDT blood test for Lupus patients that will assess disease status, predict flares and match patients with best drug options. Filed patents protect AMPEL’s genomic platform, bioinformatic tools and machine learning algorithms that were developed in-house and are wholly owned by the company. AMPEL’s exclusive curated database of 10,000 Lupus patients is the world’s largest and fuels machine learning predictions. AMPEL validated it’s approach with 5+Pharma customers by accelerating trial success by identifying patients for trials that express the target/pathway of the drug being tested.

To learn more about Ampel, visit http://ampelbiosolutions.com/

Contact:
Amrie Grammer, Chief Operating Officer
434-296-2675

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved